Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BYEndocrinology

Antioxidant therapy, N-acetyl-L-cysteine, effects on pancreatic β cells: therapeutic promise or potential harm?

  • Meg Schuurman1,2
  • Jonathan Nguyen2
  • Malina Barillaro1
  • Nica Borradaile2
  • Rennian Wang1,2,3
  1. 1Children's Health Research Institute, University of Western Ontario, London, ON N6C 2V5, Canada.
  2. 2Department of Physiology & Pharmacology, University of Western Ontario, London, ON N6A 5C1, Canada.
  3. 3Department of Medicine, University of Western Ontario, London, ON N6A 5C1, Canada.
Read full textDOICite

Abstract

N-acetyl-L-cysteine (NAC) is a widely used antioxidant with increasing public interest in its use for treating metabolic disease, yet its effects on pancreatic β cells remain incompletely understood. Most studies focus on NAC's benefits under pathological conditions-such as obesity, high-fat diet exposure, and type 2 diabetes-where oxidative stress impairs β-cell function, identity, and survival. In these contexts, NAC can reduce oxidative damage, preserve insulin secretion, and limit islet fibrosis. However, far fewer studies examine NAC under normal physiological or aging conditions, where moderate reactive oxygen species levels are required for β-cell signaling and glucose-stimulated insulin secretion. Emerging evidence shows that excessive antioxidant exposure during non-pathological states may disrupt redox-dependent pathways, suppress insulin biosynthesis and exocytosis, and contribute to reductive stress. Here, we review the current evidence of NAC's impact on β cells across physiological, aging, and pathological settings. Moreover, we highlight that NAC can be protective or detrimental depending on redox state, metabolic environment, and dosing, which emphasizes the need for careful consideration of antioxidant use in humans.

Related

  1. Myeloid-driven immunosuppression as a context-dependent therapeutic bottleneck in pancreatic ductal adenocarcinoma
    Kai Sun, Lei Yang, Jingjing Li +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  2. Bidirectional regulation of pancreatic stellate cell-mediated pancreatic fibrosis by prostaglandin subtypes: mechanisms and therapeutic implications
    Sichun Wang, Hubo Chen, Lina Wang
    Molecular Biology ReportsPeer-reviewedCC BY-NC-ND 4.0Full textSurgery & anaesthesiaPMC
  3. Preoperative Total Iron‐Binding Capacity Is a Potential Surrogate Marker of Long‐Term Outcomes After Pancreatectomy for Pancreatic Cancer
    Taishi Yamane, Hiromitsu Hayashi, Hiroshi Sawayama +7
    Annals of gastroenterological surgeryPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. A Review on Cyanidin-3-O-glucoside Antioxidant Activity, Food Technology Applications and Therapeutic Uses.
    Eiko Osawa-Martínez, Yury Rodríguez-Yáñez, Benito Minjarez +4
    Journal of food sciencePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. Loss of the Y chromosome drives basal identity and metastatic potential via epigenetic reprogramming in pancreatic cancer
    M. Dorsch, F. E. G. Beaudry, A. K. Baginska +31
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{schuurman2026antioxidant,
  title = {{Antioxidant therapy, N-acetyl-L-cysteine, effects on pancreatic β cells: therapeutic promise or potential harm?}},
  author = {Meg Schuurman and Jonathan Nguyen and Malina Barillaro and Nica Borradaile and Rennian Wang},
  journal = {Endocrinology},
  year = {2026},
  month = sep,
  doi = {10.1210/endocr/bqag114},
  url = {https://europepmc.org/article/MED/42856074},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Antioxidant therapy, N-acetyl-L-cysteine, effects on pancreatic β cells: therapeutic promise or potential harm?
AU  - Meg Schuurman
AU  - Jonathan Nguyen
AU  - Malina Barillaro
AU  - Nica Borradaile
AU  - Rennian Wang
PY  - 2026
DA  - 2026/09/01
JO  - Endocrinology
DO  - 10.1210/endocr/bqag114
UR  - https://europepmc.org/article/MED/42856074
AB  - N-acetyl-L-cysteine (NAC) is a widely used antioxidant with increasing public interest in its use for treating metabolic disease, yet its effects on pancreatic β cells remain incompletely understood. Most studies focus on NAC's benefits under pathological conditions-such as obesity, high-fat diet exposure, and type 2 diabetes-where oxidative stress impairs β-cell function, identity, and survival. In these contexts, NAC can reduce oxidative damage, preserve insulin secretion, and limit islet fibrosis. However, far fewer studies examine NAC under normal physiological or aging conditions, where moderate reactive oxygen species levels are required for β-cell signaling and glucose-stimulated insulin secretion. Emerging evidence shows that excessive antioxidant exposure during non-pathological states may disrupt redox-dependent pathways, suppress insulin biosynthesis and exocytosis, and contribute to reductive stress. Here, we review the current evidence of NAC's impact on β cells across physiological, aging, and pathological settings. Moreover, we highlight that NAC can be protective or detrimental depending on redox state, metabolic environment, and dosing, which emphasizes the need for careful consideration of antioxidant use in humans.
SN  - 0013-7227
SN  - 1945-7170
ER  -